

# Treatment Options for Plaque Psoriasis: Effectiveness and Value

---

## Voting Questions for November 18, 2016 Public Meeting

These questions are intended for the deliberation of the New England CEPAC voting body at the public meeting.

---

**Patient population** for all voting questions: *Patients with moderate-to-severe plaque psoriasis for whom treatment with topical therapies, older systemic therapies, and/or phototherapy has been ineffective, contraindicated, or not tolerated.*

**Comparator** for all voting questions unless specified otherwise: *continued untargeted therapy.*

- 1) Is the evidence adequate to demonstrate that the net health benefit of apremilast is as good as that provided by any of the TNF- $\alpha$  inhibitors?

Yes                      No

- 2) Is the evidence adequate to distinguish the net health benefit *among* the IL-17A targeted drugs secukinumab, ixekizumab, and brodalumab?

Yes                      No

*If no...*

- a. Is the evidence adequate to demonstrate that the net health benefit of [IL-17A drugs as a class] is better than that provided by adalimumab?

Yes                      No

- b. Is the evidence adequate to demonstrate that the net health benefit of [IL-17A drugs as a class] is better than that provided by etanercept?

Yes                      No

- c. Is the evidence adequate to demonstrate that the net health benefit of [IL-17A drugs as a class] is better than that provided by infliximab?

Yes                      No

3) Is the evidence adequate to demonstrate that the net health benefit of ustekinumab is better than that provided by adalimumab?

Yes                      No

4) Is the evidence adequate to demonstrate that the net health benefit of ustekinumab is better than that provided by etanercept?

Yes                      No

5) Is the evidence adequate to demonstrate that the net health benefit of ustekinumab is better than that provided by infliximab?

Yes                      No

6) Given the available evidence on comparative effectiveness and incremental cost-effectiveness using estimated discounted prices for private insurers presented in the report, and taking into account other benefits, disadvantages, and contextual considerations, what is the long-term value for money of the following drugs compared to continued untargeted therapy?

Adalimumab

Etanercept

Infliximab

Ustekinumab

Secukinumab

Ixekizumab

Brodalumab

Apremilast

a. High                      b. Intermediate                      c. Low

7) Given the available evidence on comparative clinical effectiveness and incremental cost-effectiveness, and taking into account other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with [any IL-17A drug] versus etanercept?

a. High                      b. Intermediate                      c. Low